Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Pfizer’s Oncology leadership on Sunday, April 6, 2014 at 1:30 p.m. Pacific Daylight Time, in connection with the presentation of the final results of the PALOMA-1 Phase 2 trial for palbociclib at the American Association for Cancer Research (AACR) Annual Meeting 2014. There will be a Q&A session following the presentation during the webcast.

This webcast is specifically tailored to the investment community. To view and listen to the webcast, visit our website at www.pfizer.com and click on the “Review of Palbociclib Phase 2 PALOMA-1 Results at AACR Annual Meeting 2014” webcast link in the For Investors section located on the lower right-hand corner of that page. Information on accessing and pre-registering for the webcast will be available at www.pfizer.com beginning today. Participants are advised to pre-register in advance of the conference call.

You can also listen to the conference call by dialing either (866) 246-2545 in the United States and Canada or (706) 634-2365 outside of the United States and Canada. The password is “AACR 2014”.

For medical and general questions about palbociclib, including information about palbociclib clinical trials, please call 1-800-438-1985.

Visitors to www.pfizer.com will be able to view and listen to an archived copy of the webcast of the conference call.

About PALOMA-1

PALOMA-1 (also known as Study 1003 and TRIO-18) is a Phase 2 trial designed to assess the progression-free survival (PFS) of palbociclib (125 mg once daily for three out of four weeks in repeated cycles) in combination with letrozole versus letrozole alone (2.5 mg once daily on a continuous regimen) in post-menopausal women with ER+, HER2- advanced breast cancer. PFS is comprised of time from randomization to time of disease progression or death from any cause. PALOMA-1 was conducted in collaboration with the Jonsson Cancer Center’s Revlon/UCLA Women’s Cancer Research Program. PALOMA-1 is a multi-center trial with 101 global sites participating.